Association of Programmed Death‐Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma Receiving Crizotinib

BACKGROUND: Programmed death‐ligand 1 (PD‐L1) expression is associated with clinical outcomes of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (ADC) treated with tyrosine kinase inhibitors (TKIs). However, whether PD‐L1 expression plays a role in anaplastic lymphoma kinase (ALK)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Yang, Ching‐Yao, Liao, Wei‐Yu, Ho, Chao‐Chi, Chen, Kuan‐Yu, Tsai, Tzu‐Hsiu, Hsu, Chia‐Lin, Liu, Yi‐Nan, Su, Kang‐Yi, Chang, Yih‐Leong, Wu, Chen‐Tu, Liao, Bin‐Chi, Hsu, Chia‐Chi, Hsu, Wei‐Hsun, Lee, Jih‐Hsiang, Lin, Chia‐Chi, Shih, Jin‐Yuan, Yang, James Chih‐Hsin, Yu, Chong‐Jen
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Lung Cancer
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7418350/
https://ncbi.nlm.nih.gov/pubmed/32386255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0088
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares